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Abstract
Peritoneal fibrosis is a frequent complication of peritoneal dialysis following repeated low grade inflammatory and pro-
fibrotic insults. This pathological process may lead to ultrafiltration failure and eventually to the discontinuing of the
therapy. Fibrosis is linked to epithelial to mesenchymal transition (EMT) of the peritoneal mesothelial cells, which acquire
invasive and fibrogenic abilities. Here, we analyzed the role of the transforming growth factor-activated kinase-1 (TAK1) in
the EMT of primary mesothelial cells from human peritoneum. The inhibition of TAK1 in mesenchymal-like mesothelial cells
from the effluents of patients undergoing peritoneal dialysis led to the reacquisition of the apical to basolateral polarity, to
increased expression of epithelial and to down-regulation of mesenchymal markers. TAK1 inhibition also resulted in
decreased migratory/invasive abilities of effluent-derived mesothelial cells. Simultaneous inhibition of ERK1/2 and TAK1
pathways did not lead to an additive effect in the reacquisition of the epithelial phenotype. Inhibition of TAK1 also blocked
EMT in vitro and reduced the levels of PAI-1, which is involved in fibrosis and invasion. Analysis of signalling pathways
downstream of TAK1 involved in EMT induction, showed that TAK1 inhibition reduced the transcriptional activity of NF-kB
and Smad3, as well as the phosphorylation of c-jun, while enhancing Smad1–5–8 activity. These results demonstrate that
TAK1 is a cross-point in a network including different pro-EMT transcription factors, such as NF-kB, Snail, AP-1 and Smads.
The identification of TAK1 as a main biochemical mediator of EMT and fibrosis in mesothelial cells from human peritoneum
and the study of signalling pathways induced by its activity may be relevant in the design of new therapies aimed to
counteract peritoneal fibrosis.
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Introduction
The main complication of the peritoneal dialysis is the
instauration of peritoneal fibrosis. This process is associated with
the progressive decrease of the dialytic function of the peritoneal
membrane and eventually with the discontinuing of the therapy
[1]. The establishment of peritoneal fibrosis has been associated
with the epithelial to mesenchymal transition (EMT) of the
peritoneal mesothelial cells monolayer [2]. Repeated low grade
inflammatory stimuli may induce peritoneal mesothelial cells to
lose intercellular junctions, to undergo morphological changes
and to progressively acquire invasive, fibrogenic and angiogenic
abilities [1]. EMT and fibrosis of the peritoneal membrane have
similarities with analogous inflammation-related pathologic
alterations of other tissues and organs, occurring in liver, heart,
the pleural membrane, and in the kidney [3,4]. EMT is thought
to be driven by extracellular stimuli, and among them
transforming growth factor-(TGF)b1 often plays a major role
[5,6] [7,8]. Peritoneal mesothelial cells (MCs) constitutively
produce low levels of TGF-b1, as well as other factors, such as
bone morphogenic proteins (BMPs), that may counteract the
induction of EMT [9,10]. Besides TGF-b1 and BMPs, other
stimuli, such as FGF, CTGF, TNFa, IL-1b, HGF as well as
extracellular matrix (ECM) proteins such as fibronectin and
collagen may play a role in the induction of peritoneal EMT and
fibrosis [1]. Overall, the balance between pro- and anti-EMT
extracellular factors may determine the status of the MCs. This
concept implicates that, at least during the first stages, the
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epithelial/mesenchymal status of MCs is reversible, and may
actively be modified by extracellular factors. To this purpose, the
reversal from a mesenchymal to an epithelial status (MET:
Mesenchymal to Epithelial transition) has been already demon-
strated in MCs [9,10,11], and may depend on the presence of
proteins of the TGFb family such as BMP7, HGF, corticosteroids
or vitamin D analogues [9,10,12,13].
A common hallmark in EMT studies is the downregulation of
epithelial markers. Among them, E-cadherin downregulation is
often followed by replacement with more motile cadherins, such as
N-cadherin [14]. Transcription factors, such as those of the Snail,
Zeb and HLH families, play a major role in transcriptional
downregulation of E-cadherin and other genes involved in EMT
[15]. Besides E-cadherin, other epithelial markers, such as
cytokeratins, become downregulated during EMT whereas
proteins related to the mesenchymal state or fibrosis, such as
vimentin, collagens, fibronectin and PAI-1 are upregulated [6,7].
Many signalling pathways are involved in the induction of EMT
and its reversal. Smad2–3 are directly induced by TGF-b1 and
have a primary role in peritoneal EMT and fibrosis. Actually, the
balance between TGF-b1 activated Smad2–3 and BMP-activated
Smad1–5–8 controls the EMT status of the cell in many
experimental systems [9,16]. Besides this, the induction of EMT
and fibrosis may be regulated by Smad-independent pathways,
such as GSK3b, b-catenin, NF-kB, PI3K, ERK, p38 and JNK
MAPK [7,17,18,19].
TGFb-activated kinase (TAK)1, also known as MEKK7, is a
member of the MAPKKK family and is activated by different
stimuli, such as BMPs, Toll like receptors (TLR), IL-1b and
TNFa [20,21] TAK1 is involved in the regulation of innate and
adaptive immunity, in vascular development and keratinocyte,
hematopoietic and hepatocyte survival [22]. TAK1 activation
involves the binding to the TAK-associated binding protein 1
(TAB1), TAB2 and TAB3 and interaction with E3 ubiquitin
ligase TRAF6, that directly interacts with a consensus motif
present in TGFbRI [23]. The TGFbRI-TRAF6 interaction is
required for TGFb-induced autoubiquitylation of TRAF6 and
subsequent activation of p38 and JNK, through activation of their
intermediate kinases MKK3/MKK6, and of NF-kB pathway
[24]. Despite the ability of TAK1 in transducing signals from a
wide array of inflammatory and pro-fibrotic stimuli, an extensive
study on its role in the establishment and maintenance of EMT
and fibrosis has not been performed so far. We have recently
demonstrated that TAK1 controls E-cadherin downregulation
and the acquisition of a spindle-like cellular shape in MCs
stimulated with TGF-b1 in combination with IL-1b [19]. Here,
we demonstrate that TAK1 is a key regulator of EMT and
fibrosis in MCs, and its inhibition mediates MET. TAK1 controls
the down-regulation of E-cadherin and the induction of
mesenchymal markers and proteins implicated in fibrosis such
as N-cadherin, type I collagen, fibronectin and PAI-1. Moreover,
wound healing and invasion in in vitro assays were reduced upon
TAK1 inhibition. TAK1 controls the activity of different
transcription factors such as NF-kB, Snail, AP-1, as well as
Smad2–3/Smad1–5–8 balance. Thus, TAK1 is at the cross-road
of different receptors involved in inflammation and EMT, and is
upstream of relevant pathways involved in EMT regulation.
Given that EMT of MCs is central to the onset of peritoneal
fibrosis and angiogenesis, and that there is no effective treatment
for the progressive loss of peritoneal dialytic capacity in patients
undergoing peritoneal dialysis (PD), these results provide possible
routes for therapeutic intervention.
Results
TAK1 inhibition leads to the reversal of the EMT
phenotype (MET) in MCs derived from peritoneal effluent
of PD patients
To analyze the role of TAK1 in the EMT of MCs, we used
MCs isolated from peritoneal effluent of 20 PD patients that
have already undergone EMT in vivo (Table 1). These cells are
often distinguished in epithelioid, and non epithelioid, and their
stage of transdifferentiation correlates with the progression of
peritoneal damage and the time of PD treatment [25]. We
detected basal level of endogenous TAK1 phosphorylation in
these cells, which was greatly enhanced by treatment with
okadaic acid (OA) (Figure S1A). To inhibit TAK1 basal
activity, we treated these cells with a specific pharmacological
inhibitor (NP-009245, 600 nM) for 72 h [26]. This is a derivative
of 5Z-7-oxozeanol, a pharmacological compound that has been
recognized as a selective and irreversible inhibitor of TAK1 ATP
binding in in vitro studies [26]. Interestingly, we observed that
treatment with NP-00924 also decreases TAK1 expression
(Figure S1B). TAK1 inhibition led to the loss of spindle-like
shape and to a partial reacquisition of the ‘cobblestone’
epithelial-like phenotype (Fig. 1A). The inhibition of ERK1/2
pathway, which causes EMT reversal [18], led to similar results.
To inhibit ERK1/2 pathway we used CI-1040, an highly specific
allosteric inhibitor of MEK1 activity [27]. TAK1 inhibition
increased E-cadherin, as shown in a western blot analysis
(Fig. 1B) and in RT-PCR (Fig. 1C), while reducing N-cadherin
mRNA (Fig. 1D) and protein (Fig. 1B) expression. The
simultaneous treatment with MEK1 and TAK1 pharmacologic
inhibitors did not further increase E-cadherin levels, with respect
to the TAK1 inhibitor alone (Fig. 1C). Also, treatment with
both pharmacological inhibitors did not increase the reacquisi-
tion of a ‘cobblestone’ phenotype (data not shown). TAK1
inhibition led also to an increment of cytokeratin expression
(Fig. 1E), and to an increased ZO-1 localization at intercellular
junctions (Fig. 1F).
TAK1 inhibition limits the expression of mesenchymal
markers by MCs derived from peritoneal effluent of PD
patients
Next, we asked whether TAK1 may also control the expression
of mesenchymal markers in MCs from peritoneal effluent. MCs
produced bundles of fibronectin, which were reduced upon
TAK1 inhibition with pharmacological inhibitor (Fig. 2A). WB
and RT-PCR analysis (Fig. 2B–C) confirmed the reduction of
fibronectin at protein and mRNA levels. Vimentin was also
reduced in MCs treated with TAK1 inhibitor (Fig. 2B).
Mesothelial cells, due to their mesenchymal origin, express
constitutively vimentin, and its levels increase upon EMT
induction [2]. We confirmed the effect of TAK1 on E-cadherin
by specific knockdown. After TAK1 knockdown, E-cadherin
protein (Fig. 2D) and mRNA (Fig. 2E) levels were markedly
increased. Also, fibronectin expression was reduced upon specific
TAK1 silencing (Fig. 2D). These results suggest that TAK1
inhibition may counteract the in vivo EMT of MCs from
peritoneal effluent of patients undergoing PD. TAK1 inhibition
promotes the reversal to a ‘cobblestone’ phenotype, the increase
of epithelial markers, such as E-cadherin, cytokeratin, the
membrane localization of ZO-1, and the decrease of markers
associated EMT and fibrosis, such as N-cadherin, vimentin and
fibronectin.
Reversal of EMT by TAK1 Inhibition
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TAK1 inhibition blocks the EMT in MCs induced in vitro
by a combination of TGF-b1 and IL-1b
We then studied the role of TAK1 in the induction of EMT in
vitro upon stimulation of primary MCs from human omentum
(HPMCs) with TGF-b1 in combination with IL-1b for 24 h.
Under these conditions, these cells acquire a spindle-like
phenotype, undergo E/N-cadherin switch and increase FN and
vimentin expression [2,18,19]. TAK1 inhibition limited E-
cadherin mRNA downregulation upon T/I induction in these
cells (Fig. 3A). Interestingly, E-cadherin downregulation inversely
correlated with Snail expression (Fig. 3B). TAK1 inhibitor
exerted an analogous effect in the modulation of E-cadherin and
Snail levels when EMT was induced using TGF-b1 alone
(Fig. 3C–D). TAK1 inhibition also reduced fibronectin (Fig. 3E)
and type I collagen expression in RT-PCR experiments (Fig. 3F).
These results demonstrate that TAK1 inhibition blocks in vitro
EMT induction in MCs treated with TGF-b1 alone or in
combination with IL-1b.
TAK1 controls the activation of multiple transcription
factors relevant for the induction of EMT and fibrosis
We next analysed signalling pathways induced by TAK1 that
may be relevant for the induction of EMT and fibrosis in MCs.
We have already demonstrated a major role for the ERK1/2-
NF-kB pathway in the induction and maintenance of EMT in
MCs [18]. As expected, TAK1 inhibition led to a markedly
reduced NF-kB transcriptional activity in MeT-5A cells in basal
conditions and upon stimulation with TGFb in combination with
IL-1b (T/I) (Fig. 4A). We analyzed Smad3 activity, which is
involved in the onset of peritoneal fibrosis after exposure to
TGF-b1 [28]. TAK1 inhibition led to reduced PAI-1 promoter
activity, which is controlled by Smad3 [29] (Fig. 4B). Moreover,
TAK1 inhibition led to a reduction of both c-jun and Smad3 c-
terminal phosphorylation after T/I stimulation in MCs
(Fig. 4C). In addition, PAI-1 protein levels were markedly
reduced upon TAK1 inhibition (Fig. 4C). Interestingly, Smad1–
5–8 transcriptional activity, as well as Smad1–5 c-terminal
phosphorylation, were enhanced by TAK1 inhibition (Fig. 4C–
D). Also, specific TAK1 silencing led to increased Smad1–5
phosphorylation and reduced levels of PAI-1 expression
(Fig. 4E). These results were confirmed using MCs from PD
patients. Treatment of these cells with TAK1 and MEK1
inhibitors led to enhanced Smad1–5, and reduced Smad3
phosphorylation (Fig. 4F). Overall, these results suggest that
TAK1, trough the activation of multiple transcription factors, is
at the cross-road of signalling pathways controlling EMT and
fibrosis.
Table 1.
FIG. 1A 1B 1C 1D 1E 1F 2A 2B 2C 2D 2E 3A 3B 3C 3D 4A 4B 4C 4D 4E 5A 5B S1 S2
N. NE X X X
1 NE X X X X
2 E X X X
3 E X X
4 E X X
5 NE X X
6 E X X X X
7 E X X X X
8 NE X X X X
9 E X X
10 NE X X
11 NE X X
12 NE X X
13 E X X
14 E X X
15 E X X
16 E X X
17 NE X X
18 NE X X
19 NE X X
20 E X X X X
HPMC1 X X X X
HPMC2 X X X X
HPMC3 X
HPMC4 X
HPMC5 X
MeT5A X X X
doi:10.1371/journal.pone.0031492.t001
Reversal of EMT by TAK1 Inhibition
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TAK1 controls directed motility and invasion of MCs from
peritoneal effluent
We last asked whether TAK1 inhibition may affect functional
events connected with EMT. Increased cell motility and invasion
are major features of cells undergoing EMT, even in MCs, that
have been demonstrated to invade the submesothelial stroma
during transdifferentiation [2,28,30]. A transient EMT takes place
in vivo during wound healing in epithelial cells [31]. We mimicked
this physiopathologic condition performing an in vitro scratch assay
on confluent monolayers of MCs from PD patients. Pre-treatment
with TAK1 inhibitor significantly reduced the closure of the
scratch (Fig. 5A). Moreover, cell invasion through type I collagen
gels was reduced upon TAK1, as well as MEK1 inhibition
(Fig. 5B). Interestingly, the simultaneous treatment with MEK1
and TAK1 pharmacologic inhibitors did not further reduce MCs
invasion. These results demonstrate that TAK1 controls MCs
directed migration during scratch closure as well as invasion,
which are important features of the EMT program.
Discussion
In this study, we analyzed the role of TAK1 in the induction
and maintenance of EMT in MCs from peritoneal effluent of
patients undergoing PD. By means of morfological, biochemical
and functional analyses, we demonstrated that the inhibition of
TAK1 activity induces reversal towards the epithelial phenotype,
and we provided mechanistic insight about it.
In the peritoneum exposed to PD fluids, recurrent low grade
inflammatory cytokines such as TGF-b1 and IL-1b are actively
released, triggering pro-inflammatory and pro-fibrotic signals that
may ultimately lead to ultrafiltration failure and fibrosis [9] [2].
These and other cytokines may be produced by mesothelial cells,
that, as well as resident peritoneal macrophages, contribute to the
maintenance of an extracellular environment favourable to the
EMT establishing or maintenance. Interestingly, this ‘pro-EMT’
milieu may be maintained also in vitro, since MCs produce soluble
factors, like M-CSF, that induce surviving of contaminating
macrophages in mesothelial cell cultures [32], that may contribute
in sustaining EMT status of MCs. In support of our hypothesis of
an auto-perpetuating loop in MCs that have undergone EMT, we
found TAK1 basally activated in MCs from PD patients. TAK1
activity is very labile, since it is tightly controlled by phosphatases,
and p38 MAPK has a role in this regulation [19].
By using a specific pharmacological inhibitor, as well as gene
silencing, we found that TAK1 inhibition led to the reacquisition
of an apical-basolateral cell polarity, i.e. the reversal to a
‘cobblestone’ phenotype. Besides these morphological changes
(that are a first requirement for the definition of EMT), TAK1
inhibition led to an increased expression of epithelial markers,
such as E-cadherin and cytokeratins, increased ZO-1 membrane
localization, as well as downregulation of mesenchymal markers,
such as vimentin and N-cadherin. TAK1 inhibition led to the
same effect both in cells that had already undergone EMT in vivo
and in cells where EMT was induced by stimulation with TGF-b1
in combination with IL-1b. Moreover, TAK1 inhibition decreased
the expression of fibronectin, collagen1 and PAI-1. Fibronectin
and collagen1 are main components of the ECM and their
expression may induce activatory loops in MCs via interaction
with b1 and b1 integrins in MCs [2]. PAI-1 is often linked to the
induction of fibrosis, since its expression leads to a decrease of
plasmin and other protease activities, thus stabilizing the ECM
[33]. Besides this effect, PAI-1 may induce fibrosis favouring cell
detachment and interstitial migration of macrophages and
myofibroblasts [34]. This may have a role also in the case of
MCs, when invading the sub-mesothelial spaces during PD. There
are conflicting results about the ability of TAK1 in the induction of
fibrosis. Previous in vitro studies demonstrated a positive role of
TAK1 in inducing fibronectin and collagen expression in different
cell lines [35] however, a recent in vivo report demonstrated
increased liver fibrosis subsequent to spontaneous hepatocyte cell
death upon genetic disruption of TAK1 [36]. Our results,
obtained in a peculiar ex vivo setting, clearly appoint for a positive
role of TAK1 in inducing fibrosis in the peritoneal membrane.
Our in vitro results, obtained by MCs stimulation with TGF-b1
in combination with IL-1b coincide with previous studies where,
in a model of lung fibrosis, adenovirus mediated TGF-b1 gene
transfer induced severe and progressive fibrosis without apparent
inflammation, whereas IL-1b induced inflammation and progres-
sive fibrosis linked to IL-1b-dependent TGF-b1 expression [37].
To this respect, IL-1b effect was different from TNFa which
induced strong inflammation without subsequent fibrosis. MCs
from lung and peritoneum show a striking similarity. In our
experimental system, combined stimulation with TGFb1 and IL-
1b has additive effects on cell morphology and cell migration [2],
E-cadherin downregulation [18] NF-kB nuclear translocation
[18].
Moreover, combined stimulation with TGFb1 and IL-1b leads
to increased ERK1/2 phosphorylation (Figure S2A) and
increased Smad3 transcriptional activity (Figure S2B). There
are several points of cross-talk between signaling pathways
activated by TGF-b1 and IL-1b [38], and their combined use
provides a more physiological analysis for specific biological
responses. Thus, our experimental system unifies the different
proinflammatory and profibrotic insults present in injured
peritoneum in a unique pathological model, and emphasize the
role of TAK1 as common inducer of peritoneal fibrosis and
EMT. However, the fact that TAK1 inhibition is able to block the
EMT induced by TGFb1 alone demonstrates that TAK1 controls
a TGFb1 dependent pathway that is independent on the
inflammation.
Figure 1. TAK1 inhibition leads to the reversal of the EMT phenotype (MET) in MCs derived from peritoneal effluent of PD patients.
A, Confocal immunofluorescence analysis (red) of MCs from a patient undergoing PD. Cells were treated with DMSO, NP-009245, (600 nM), CI 1040
(2 mM) for 72 h. Cells were fixed and stained with rhodamine phalloidin. Nuclei were stained with Hoechst 33342 (blue). The immunofluorescence
shown is representative of three independent experiments. B, Western blots showing the expression of E-cadherin in total cell lysates of MCs. Cells
were treated with DMSO, NP-009245 (T) (600 nM), CI 1040 (CI) (2 mM), or a combination of the two pharmacological inhibitors for 72 h. Expression of
tubulin was detected as a loading control. C, Effect of TAK1 pharmacological inhibition on E-cadherin mRNA expression in MCs from patients
undergoing PD. Cells were treated as in A. Quantitative RT-PCR was performed on total RNA. Histone H3 mRNA levels were used for normalization.
Bars represent means+s. e. m. of duplicate determinations in three independent experiments. D, Effect of TAK1 pharmacological inhibition on N-
cadherin mRNA expression in MCs from patients undergoing PD. Cells were treated with DMSO or NP-009245, (600 nM) for 72 h. Quantitative RT-PCR
was performed on total RNA. Histone H3 mRNA levels were used for normalization. Bars represent means+s. e. m. of duplicate determinations in three
independent experiments. E and F, Confocal immunofluorescence analysis of MCs from patients undergoing PD. Cells were treated with DMSO or
NP-009245, (600 nM) for 72 h. Cells were fixed and stained with a monoclonal antibody against cytokeratin (red) (D) or a polyclonal antibody against
ZO-1 (green) (E). Nuclei were stained with Hoechst 33342 (blue). All data are representative of at least three independent experiments. * p,0.05
versus DMSO treated cells.
doi:10.1371/journal.pone.0031492.g001
Reversal of EMT by TAK1 Inhibition
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In our system, TAK1 regulates the expression of epithelial and
fibrotic markers essentially at the level of mRNA expression,
since we found concordance between mRNA and protein
expression of E-cadherin, type I collagen, and fibronectin. We
thus analyzed the role of TAK1 in the induction of different
transcription factor activities. TAK1 controls the activation NF-
kB, c-jun and Smad3. All these transcription factors have been
shown to induce EMT and fibrosis [39] [40,41]. In particular,
PAI-1 transcription is mainly induced by Smad3 and AP-1.
Interestingly, TAK1 may affect both transcription factors since it
controls c-jun phosphorylation, which is a component of AP-1
complex. However, these transcriptional factors may act in
Figure 2. TAK1 inhibition limits the expression of mesenchymal markers by MCs derived from peritoneal effluent of PD patients. A,
Confocal immunofluorescence (red) of MCs from a patient undergoing PD. Cells were treated with DMSO or NP-009245 (600 nM) for 72 h. Cells were
fixed and stained with a monoclonal antibody against fibronectin. Nuclei were stained with Hoechst 33342 (blue). The immunofluorescence shown is
representative of three independent experiments. B, Western blots showing the expression of fibronectin, E-cadherin and vimentin in total cell
lysates of MCs treated with DMSO, NP-009245 (600 nM) or CI-1040 (2 mM) for 72 h. Expression of tubulin was used as a loading control. The results
shown are representative of three independent experiments. C, Effect of TAK1 pharmacological inhibition on fibronectin and E-cadherin mRNA
expression in MCs from patients undergoing PD. Quantitative RT-PCR was performed on total RNA from MCs treated as in A. Histone H3 mRNA levels
were used for normalization. Bars represent means+s. e. m. of duplicate determinations in three independent experiments. D, Western blots showing
the expression of E-cadherin, fibronectin and TAK1 in total cell lysates of MCs transfected with either control or specific TAK1-targeting siRNAs. Scr,
cells transfected with control siRNA. Data are representative of three independent experiments. E, Effect of TAK1 siRNA silencing on E-cadherin mRNA
expression in MCs. Cells were treated as in D. Quantitative RT-PCR was performed; bars represent means+s. e. m. of duplicate determinations in three
independent experiments. * p,0.05 versus siScrambled treated cells.
doi:10.1371/journal.pone.0031492.g002
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synergy, since many studies have reported a cooperation
among different transcription factors in the induction of
transcriptional activity. Smad3–4 may form a transcriptional
repressor complex with Snail that mediate EMT in tumours [42].
Functional and physical interactions between Smad3–Smad4
and c-Jun-c-Fos may mediate TGFb induced transcriptional
activity [43] [44,45].
It has been widely demonstrated that TAK1 controls NF-kB
and c-jun [21], whereas TAK1 activity on the Smads is object of
controversy. TAK1 is not required for TGFb induced Smad2
activation [22]; TAK1 may directly phosphorylate Smad1 at c-
terminus, thus enhancing its activity [46]. The reported differences
about the effect of TAK1 may refer to different experimental
systems used. In our case, TAK1 inhibition led to a decrease of
Smad3 c-terminal phosphorylation, which is linked to transcrip-
tion activity. Moreover, TAK1 may also affect Smad3 activity
indirectly, inducing the degradation of the inhibitor SnoN [47],
that counteracts Smad3 nuclear activity.
Besides controlling Smad3 activity, TAK1 may have a broader
effect on the balance between Smad2–3 and Smad1–5–8, that
plays a major role in EMT status [6]. In our system, TAK1
inhibition led to an increased transcriptional activity of Smad1–5–
8 as measured as BRE-luc promoter activation, as well as
increased c-terminal Smad1–5 phosphorylation.
Figure 3. TAK1 inhibition limits the induction of EMT in HPMCs treated with TGF-b1 in combination with IL-1b. Effect of TAK1
pharmacological inhibition on E-cadherin (A, C), Snail (B, D), fibronectin (E) and type I collagen (F) mRNA expression in HPMCs. Quantitative RT-PCR
was performed on total RNA from MCs pre-treated with DMSO, or NP-009245, (600 nM) for 1 h and then left untreated or stimulated with TGF-b1
0.5 ng/ml) in combination with IL-1b 2 ng/ml) (T/I) or TGF-b1 alone at the same concentration (T) for 24 h. Histone H3 mRNA levels were used for
normalization. Bars represent means+s. e. m. of duplicate determinations in three independent experiments. * p,0.05 versus DMSO treated cells.
doi:10.1371/journal.pone.0031492.g003
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Figure 4. TAK1 controls the activation of multiple transcriptional factors relevant for the induction of EMT and fibrosis. A, Effect of
TAK1 inhibition on NF-kB transcriptional activity. MeT-5A cells were transiently transfected with the KBF-luc reporter plasmid together with Renilla
luciferase. Cells were pretreated with NP-009245 (600 nM) for 12 h and then left untreated (NT, gray bars) or co-stimulated for 9 h with TGF-b1
(0.5 ng/ml) in combination with IL-1b (2 ng/ml) (T/I). Bars represent means+s. e. m. of triplicate determinations in three independent experiments. B,
Effect of TAK1 inhibition on PAI-1 transcriptional activity. MeT-5A cells were transiently transfected with a PAI-1 reporter plasmid together with a
Renilla luciferase-coding plasmid. Cells were stimulated as above. Bars represent means+s. e. m. of triplicate determinations in three independent
experiments C, Western blots showing the expression of phospho-Smad3, phospho-Smad1–5, PAI-1 and phospho-c-jun in total cell lysates of HPMCs
treated for different times with TGF-b1 0.5 ng/ml) in combination with IL-1b (2 ng/ml) (T/I). Expression of tubulin was used as a loading control. The
results shown are representative of three independent experiments. D, Effect of TAK1 inhibition on Smad1–5–8 transcriptional activity. MeT-5A cells
were transiently transfected with the BRE-luc reporter plasmid together with a Renilla luciferase-coding plasmid. Cells were pretreated with NP-
009245 (600 nM) for 12 h and then left untreated (NT, gray bars) or co-stimulated for 12 h with TGF-b1 (0.5 ng/ml) in combination with IL-1b (2 ng/
ml) (T/I). Bars represent means+s. e. m. of triplicate determinations in three independent experiments. E, Western blots showing the expression of
phospho-Smad1–5, PAI-1 and TAK1 in whole cell lysates of HPMCs transfected with either control or specific TAK1-targeting siRNAs and then left
untreated or stimulated for 4 h with TGF-b1 (0.5 ng/ml) in combination with IL-1b (2 ng/ml) (TI). Scr: cells transfected with control siRNA. Data are
representative of three independent experiments F, Western blot showing the expression of phospho-Smad1–5–8 in MCs from a patient undergoing
PD. Cells were treated with DMSO, CI 1040 (2 mM), NP-009245, (600 nM) for 24 h. Expression of tubulin was used as a loading control. All data are
representative of at three independent experiments. * p,0.05 versus corresponding sample treated with DMSO.
doi:10.1371/journal.pone.0031492.g004
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Our previous study demonstrated that ERK1/2 inhibition was
permissive for EMT reversal in cells from PD patients [18]. We
analyzed whether in our experimental model ERK1/2 and TAK1
may act independently or have common downstream targets. In
some experiments, we treated MCs simultaneously with inhibitors
of both MEK1 and TAK1. MEK1 inhibition along with TAK1
inhibition did not have additional effects in E-cadherin or
fibronectin expression, nor in morphological changes. This
suggests that ERK1/2 and TAK1 activities may converge to the
same common targets. We identified in a previous study an
ERK1/2/NF-kB/Snail pathway controlling EMT in MCs where
both TAK1 and ERK1/2 activities may converge [18], although
we do not exclude that these two kinases may have specific effects.
We last focused on the functional role of TAK1 in MCs
motility. MCs invasion through the basal lamina to the
submesothelial stroma has a major role in the induction of
vasculopathy and fibrosis [1] [28]. On the other hand, directed
migration of MCs may be useful to repopulate areas of the
peritoneal membrane that become devoid of cells, especially after
peritonitis episodes [48].
We performed an in vitro scratch assay on MCs monolayer and
we found that TAK1 inhibition significantly reduced closure of the
scratch in a MCs monolayer as well as invasion through collagen
gel. These results suggest that TAK1 may be functionally
implicated in the increased migration and invasion of MCs during
EMT, but further in vivo analyses would be needed to elucidate
the role of TAK1 in the migration of MCs.
TAK1 was characterized as a kinase induced by TGF family
members and also by other inflammatory stimuly such as IL-1b,
TNFa and TLR ligands; however, an extensive study on the role
of this kinase in the establishment and maintenance of EMT and
fibrosis has never been performed. Here, the role of TAK1 in
EMT and fibrosis is extensively characterized in a peculiar
experimental system based on primary MCs from PD patients that
have undergone EMT in vivo. We propose TAK1, with its ability in
orchestrating the activation of different transcription factors, as a
central point of control of EMT and fibrosis (Fig. 6). To this
respect, this study is relevant both for peritoneal dialysis research
and for the basic understanding of molecular mechanisms
underlying EMT and fibrosis.
Figure 5. TAK1 controls wound closure and invasion on type I Collagen gel in MCs from peritoneal effluent. A, Effect of TAK1 inhibition
on wound closure. Left, MCs from a patient undergoing PD were allowed to reach 100% confluency in a 6 well plate. MCs were pre-treated with
DMSO or NP-009245 (600 nM) for 24 h in culture medium supplemented with 10% FCS. A scratch wound was created on the cell surface using a
micropipette tip. The wound area was photographed every 30 min for 24 h by bright field microscopy (46magnification). The width of the wound
was measured and the wound closure rate was calculated. 9 different points from 3 different scratches were analyzed per condition. Only the
beginning and the end of the test analysis is shown. The result described is representative of 5 independent experiments. Right, quantification of the
experiment described before. P *,0.05 compared to DMSO-treated cells. B, Effect of TAK1 and MEK1 inhibition on MCs invasion on type I Collagen
gel. MCs were pre-treated with DMSO, NP-009245 (600 nM) or CI-1040 (2 mM) for 24 h. Cells were allowed to invade type I Collagen gels for 24 hours.
Invading cells were fixed and nuclei were counted. Nuclei were counted in ten fields per sample using a fluorescence microscope (406
magnification). Each experiment was carried out in duplicate, and at least 5 experiments were performed. P *,0.05 compared to DMSO-treated cells.
doi:10.1371/journal.pone.0031492.g005
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Materials and Methods
Isolation and culture of MCs
Effluent-derived MCs were isolated from clinically stable PD
patients using a method described previously [49]. Briefly,
nocturnal peritoneal dialysates from clinically stable patients are
drained and processed immediately. Bags are hanged for 3–
4 hours in an incubator at 4uC to facilitate the accumulation of
floating cells at the bottom of the bags. The supernatant is then
carefully removed by vacuum with a sterile pipette, leaving
approximately 200 mL of sediment. The cells are transferred to
four 50-mL tubes, centrifuged at 1200 rpm for 10 minutes, and
washed twice with phosphate-buffered saline (PBS). The cell
pellets are suspended in 5–7 mL of culture medium, counted in a
Neubauer chamber, seeded in 25-cm2 tissue culture flasks, and
incubated at 37uC in a humidified atmosphere with 5% CO2.
Cells were cultured in Earle’s 199 medium supplemented with
20% fetal calf serum, 50 U/ml penicillin, 50 mg/ml streptomycin,
and 1% Biogro-2 (containing insulin, transferrin, ethanolamine,
and putrescine) (Biological Industries, Beit Haemek, Israel), and
after 10–15 days cultures reached confluence. The morphological
features of cells in confluent cultures remained stable during the
two to three passages used for experiments. Confluent MC
cultures from PD effluents show one of two major phenotypes,
epithelial-like (epithelioid) or non-epithelioid, which remain stable
for two to three cell passages [25]. Epithelioid cells have a
cobblestone appearance, and they are often morphologically
indistinguishable from primary omentum derived mesothelial cells.
However, these effluent-derived mesothelial cells with epithelioid
morphology already show down-regulation of the epithelial
markers E-cadherin and cytokeratins, up-regulation of the
mesenchymal marker Snail, and are half as high as HPMC in
vertical confocal images, indicating that the E cells have initiated
the EMT process (early EMT). On the other hand, effluent-
derived non-epithelioid cells have a spindle-like fibroblastic shape,
and are in advanced steps of the EMT process (late EMT). These
non-epithelioid cells express high levels of mesenchymal molecules
including fibronectin and type I collagen, show increased
migratory/invasive capacity, and express high amounts of pro-
fibrotic and angiogenic factors such as VEGF, TGF-b1, CXCL8.
[2][25][50].
To control for fibroblast contamination, the purity of HPMC
and effluent-derived MC cultures was determined from the
expression of the standard mesothelial markers, intercellular
adhesion molecule (ICAM)-1 and cytokeratins [1]. MCs expressed
high levels of ICAM-1; this allows these cells to be easily
distinguished from peritoneal fibroblasts [18]. Moreover, HPMCs
express high levels of epithelial cytokeratins, which are slowly
downregulated during the EMT process. As shown in Figure S3,
MCs from PD effluents are still generally expressing cytokeratins,
although at low levels. MC cultures are generally negative for the
endothelial marker CD31 and the pan-leukocyte marker CD45.
When isolating both omentum- and peritoneal effluent-derived
MCs, we generally obtain highly purified cell populations, with
,5% contaminant cells, as determined by FACS analysis (Figure
S4). Purified samples with .5% contaminant cells are routinely
discarded.
HPMCs were obtained by digestion of omentum samples from
patients who were undergoing unrelated abdominal surgery [51].
The samples were digested with a 0.125% trypsin solution
containing 0.01% EDTA..Cells were cultured as above. To
induce EMT, HPMCs were treated with a combination of
human-recombinant TGF-b1 (0.5 ng/mL) and IL-1b (2 ng/mL)
(R&D Systems, Minneapolis, MN) as described previously [2]
[25]. Although both TGFb1 and IL-1b separately are able to
induce EMT phenotypic changes, combined stimulation induces a
more complete EMT [2,18,47]. The cytokine doses used are in the
range of those detected in peritoneal-dialysis fluids in the presence
of peritonitis (Lai et al., 2000) and are similar to those used in
previous studies [2,52]. The study was approved by the ethics
committee of the Hospital Universitario de la Princesa (Madrid,
Spain). Written informed consent was obtained from both PD
patients included in this study, for the use of effluent samples, and
from omentum donors prior to elective surgery.
The human MC line MeT-5A (ATCC, Rockville, MD) was
cultured in Earle’s 199 medium, as above, and stimulated with the
same doses of TGFb1 and IL-1b. MeT-5A is an untransformed
MC line, which is often used in peritoneal MC research.
Antibodies and chemicals
The monoclonal antibody against E-cadherin was purchased
from BD (Becton-Dickinson Laboratories, Mountain View, CA);
monoclonal antibodies against tubulin, pan-cytokeratin, vimentin,
and fibronectin were from Sigma (Saint Louis, MO); Polyclonal
antibodies against phospho-Smad3, phospho-Smad1–5, phospho-
c-jun, phospho-TAK1 (Thr187), TAK1 were from Cell Signaling
(Cell Signaling Technology, Danvers, MA); polyclonal antibody
against Smad3 was from Santa Cruz Biotechnology (Santa Cruz,
CA). Monoclonal antibody against N-cadherin and polyclonal
antibody against ZO-1 were from Zymed (Invitrogen, Carlsbad,
CA); monoclonal antibody against CD45-FITC was from BD
Bioscience, (San Jose`, CA); monoclonal antibody against ICAM-
1(HU5/3) was from Dr. Yan˜ez-Mo (Madrid, Spain); Fluor 647–
phalloidin and Hoechst 33342 were purchased from Invitrogen
(Carlsbad, CA). 9-Epimer-11,12-dihydro-(5Z)-7-oxozeanol was
from AnalytiCon Discovery (NP-00924), Potsdam, Germany.A-
lexa. CI 1040 was from Selleck, Houston, USA.
Western blotting
Monolayers of MCs were lysed in modified RIPA buffer
containing: 50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.1% SDS;
0.25% Nadeoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM
Figure 6. TAK1 as a checkpoint of major signalling pathways
controlling EMT and fibrosis. Rapidly induced by a wide array of
pro-inflammatory and pro-fibrotic stimuli, TAK1 activation plays a
central role in the induction of the EMT program. Besides controlling
classical inflammatory pathways, such as NF-kB and MAPKs, TAK1
activation affects Smad3/Smad1–5 balance. TAK1 activation in MCs
relies on cadherin switching, PAI-1 expression, increased ECM protein
production, as well as the acquisition of invasive abilities. See text for
details.
doi:10.1371/journal.pone.0031492.g006
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EGTA; 1 mM PMSF; 1 mg/ml each of aprotinin, leupeptin and
pepstatin; and 25 mM NaF (all from Sigma). Equal amounts of
protein were resolved by SDS-PAGE. Proteins were transferred to
Nitrocellulose membranes (Amersham Life Sciences, Little
Chalfont, UK) and probed with antibodies using standard
procedures. Nitrocellulose-bound antibodies were detected by
chemiluminescence with ECL (Amersham Life Sciences).
Confocal microscopy and immunofluorescence
Cells were fixed for 20 minutes in 3% formaldehyde in PBS,
permeabilized in 0.2% Triton X-100/PBS for 5 minutes, and
blocked with 2% BSA for 20 minutes. For E-cadherin staining,
cells were fixed and permeabilized in ice-cold methanol for
5 minutes. Secondary antibodies (conjugated to Alexa-647, -488
and -541) and Hoechst 33342 were from Pierce Chemical
Company (Rockford, IL). Confocal images were acquired using
a Leica SP5 spectral confocal microscope. The spectral technology
allows discrimination between yellow and green fluorescence.
Flow Cytometry Analysis
Confluent cultures of effluent-derived MCs were trypsinized,
washed and resuspended in PBS. A total of 16105 cells were
incubated with 100 ml of monoclonal antibody against ICAM-
1(HU5/3), washed with PBS and then incubated with 100 ml of a
1:50 dilution of an FITC-conjugated anti–mouse Ig. Alternatively,
16105 cells were incubated with 100 ml of a 1:50 dilution of a
monoclonal antibody against CD45-FITC for 20 min at 4uC and
washed with PBS. Finally, fluorescence was measured using a
FACScanH flow cytometer (Becton Dickinson Labware, Lincoln
Park, NJ).
siRNA-mediated TAK1 knockdown
1.26105 cells were seeded on 24-well plates 24 h prior
transfection. Cells were transfected overnight with either 80 pmol
ON-TARGETplus SMARTpool against human TAK1 (RefSeq
NM_145331) or the same amount of ON-TARGETplus Non-
targeting Pool and 1 ml Dharmafect 1 (Dharmacon, Lafayette,
CO) in 400 ml antibiotic-free medium per well. Transfections were
performed twice with a 48 h-interval. 72 h after the last
transfection, knockdown efficiency was determined by western
blot and cells were processed as indicated.
Cell transfection and luciferase assays
NF-kB transcriptional activity was measured by transient
transfection of MeT-5A cells with the KBF-luc reporter plasmid
and subsequent luciferase activity assay [53]. Smad3 transcrip-
tional activity was measured by transient transfection of MeT-5A
cells with the PAI-1 reported plasmid [54] and SMAD1–5–8 with
BRE-luc reporter plasmid [55] Briefly, 26105 cells were
transfected with 2 mg of reporter plasmid together with 500 ng
of the reporter plasmid pRL-null, which bears a promoter-less
Renilla luciferase gene (Promega, Madison, WI). Transfections
were performed by incubating cells for 4 hours with a mixture of
DNA and lipofectamine at a ratio of 1:2.5 (Lipofectamine 2000;
Invitrogen, Carlsbad, CA, USA) in serum-free medium. After
transfection, cells were pretreated overnight with vehicle (DMSO)
or U0126 (20 mM). Cells were then stimulated with TGF-b1 and
IL-1b for the times indicated. Luciferase activity was measured
with the dual-luciferase reporter assay system (Promega) according
to the manufacturer’s instructions and determined in a Sirius
single tube luminometer (Berthold Detection Systems GmbH,
Pforzheim, Germany). All experiments were carried out in
duplicate.
Wound healing
MCs from effluent of patients undergoing PD were allowed to
reach 100% confluency. MCs were pretreated with DMSO or
TAK1 inhibitor (NP-009245, 600 nM) for 24 h in culture medium
supplemented with 10% FCS. A scratch wound was created on the
cel surface using a micropipette tip. The wound area was
photographed by bright-field microscopy every 30 min for 24 h.
The width of the wound was measured and the wound closure rate
was calculated.
Invasion assay
Invasion assay was performed using polycarbonate inserts with
8 mm pore size (Costar, Cambridge, MA). The inserts were
precoated with 40 ml of solution type I collagen (300 mg/ml)
(PureCol, Inamed, Fremont, Canada) and incubated overnight at
37uC to allow gel formation. MCs were pre-treated 24 hours with
DMSO, NP-009245 (600 nM) or CI-1040 (2 mM) in 10% FBS M-
199 medium. 56104 MCs in 100 ml assay medium (M-199 0%
FBS) were added to the upper chamber. Invasion stimulus (10%
FBS) was added to the lower chamber in 600 ml assay medium.
MCs were allowed to invade for 24 hours. The inserts were then
fixed with 4% paraformaldehyde and non-invading cells on the
upper face of the membrane were then removed with a cotton
swab, filters were cut and nuclei of invading cells were stained with
Hoechst 33342. Invading cells were counted in ten fields per
sample using a fluorescence microscope (406 magnifications).
Each experiment was carried out in duplicate, and at least 5
experiments were performed.
Quantitative RT-PCR
Total RNA was extracted with the RNeasy kit (Qiagen GmbH,
Hilden, Germany), and the cDNA was obtained from 500 ng of
total RNA by using an Omniscript RT kit (Qiagen). Quantitative
PCR was carried out in a LightCycler (Roche Diagnostics GmbH,
Mannheim, Germany) using a SYBR Green kit (Roche Diagnos-
tics GmbH) and the following specific primer sets: 59TGAAGGT-
GACAGAGCCTCTG39 and 59TGGGTGAATTCGGGCT-
TGTT39 for E-cadherin; 59GCAAATACTGCAACAAGG39
and 59GCACTGGTACTTCTTGACA39 for Snail1; 59GCTAT-
GATGAGAAATCAACCG39 and 59GCTTCCCCATCATCT-
CCATTC39 for Collagen1; 59 CCTGAAGCTGAAGAGA-
CTTGC39 and 59CGTTTCTCCGACCACATAGGA39 for fi-
bronectin; 59GAAAACCCTTATTTTGCCCC39 and 59CACA-
GGATCTATTTTTAGCC39 for N-cadherin;59AAAGCCGCT-
CGCAAGAGTGCG39 and 59-ACTTGCCTCCTGCAAAGC-
AC39 for histone H3 (used for normalization). All experiments
were carried out in duplicate. After amplification, the PCR
products were confirmed by melting-curve analysis and gel
electrophoresis.
Statistical analysis
Statistical significance was determined with a t-test and Mann-
Whitney test with Graph pad software. P values of ,0.05 were
considered significant.
Supporting Information
Figure S1 TAK1 is endogenously phosphorylated in
MCs from peritoneal effluent of patients undergoing
PD and its inhibition leads to reduced TAK1 expression.
(A) Western blots showing the expression of phospho-TAK1
(Thr187) from total cell lysates of MCs from peritoneal effluent of
patient undergoing PD or MeT5A cells. Cells were left untreated
or stimulated for 15 minutes with okadaic acid (OA), (100 mM). E:
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epithelioid; NE: non-epithelioid. Expression of tubulin was used as
a loading control. (B) Western blots showing the expression of
phospho-TAK1 (Thr187) and TAK1 from total cell lysates of MCs
from peritoneal effluent of patient undergoing PD. Cells were left
untreated or treated for 24 h with NP-009245, (600 mM). E:
epithelioid; NE: non-epithelioid. Expression of tubulin was used as
a loading control. Two samples from an out of five analyzed are
shown.
(TIF)
Figure S2 ERK1/2 phosphorylation and SMAD3 tran-
scriptional activity is increased upon stimulation with
TGF-b1 in combination with IL-1b in MCs. (A) Western
blots showing the expression of phosphoERK1/2 in total cell
lysates of HPMCs left untreated or stimulated for 24 hours with
TGF-b1 (0.5 ng/ml), IL-1b (2 ng/ml), or a combination of both
cytokines. Expression of tubulin was detected as a loading control.
Data are representative of three independent experiments. (B)
MeT-5A cells were transiently transfected with a PAI-1 reporter
plasmid together with a Renilla luciferase-coding plasmid. Cells
were stimulated as above for 9 h. Bars represent means+s. e. m. of
a representative experiment of three performed.
(TIF)
Figure S3 Cytokeratin expression in MCs from perito-
neal effluent of patients undergoing PD. Confocal immu-
nofluorescence analysis of MCs from human omentum or from
peritoneal effluent patients undergoing PD. Cells were fixed and
stained with a monoclonal antibody against cytokeratin (red).
Nuclei are in blue.
(TIF)
Figure S4 ICAM1 and CD45 expression in MCs from
peritoneal effluent of patients undergoing PD. FACS
analysis of MCs from peritoneal effluent of 5 patients undergoing
PD. Cells were tripsinized, fixed, and were stained with
monoclonal antibodies anti-ICAM1 and anti-CD45.
(TIF)
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